Study of How Bariatric Surgery Affects Apixaban Medicine in Adults with Morbid Obesity

What this Trial Is About

Researchers are investigating how bariatric surgery, such as gastric bypass and sleeve gastrectomy, affects the way the body processes the medication apixaban. The study focuses on changes in factors like gastric pH, gastric emptying time, and gastrointestinal transit time that may influence drug absorption and metabolism after surgery. This research aims to better understand the biological availability of apixaban following these surgeries. Participants in this observational study are patients preparing to undergo gastric bypass or sleeve gastrectomy in Central Norway. Their regular prescription use of apixaban will be monitored to study its concentration in blood serum over time. The primary measurement is the area under the curve AUC of apixaban levels from baseline until one year after surgery. Participants will be followed from before surgery through one year postoperatively. Researchers will collect blood samples to measure apixaban concentration and monitor changes related to surgery. This careful observation will help clarify how bariatric surgery influences the pharmacokinetics of apixaban in patients with morbid obesity.

Bariatric Surgery and Pharmacokinetics of Apixaban